Low- and high-risk non-T non-B and T-cell acute lymphoid leukemia (ALL) in childhood: Different duration of remission and survival
✍ Scribed by Imbach, P. ;Baumgartner, C. ;Berchtold, W. ;Gautier, E. ;Gugler, E. ;Hirt, A. ;Morell, A. ;Tönz, O. ;Wyss, M. ;Zurbrügg, R. ;Wagner, H. P.
- Publisher
- John Wiley and Sons
- Year
- 1981
- Tongue
- English
- Weight
- 438 KB
- Volume
- 9
- Category
- Article
- ISSN
- 0098-1532
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In a prospective, nonrandomized trial clinical (initial WBC and chest film) and immunological (surface immunoglobulin and rosetting with pretreated sheep red blood cells) criteria were used to stratify 69 children with previously untreated acute lymphoid leukemia (ALL). Forty of 61 evaluable patients had low‐risk ALL (initial WBC ≤ 20,000/mm^3^, no mediastinal mass) and were treated less intensively. Twenty‐one of 61 patients had high‐risk ALL (initial WBC > 20,000/mm^3^ and/or mediastinal mass) and were treated more intensively. Of the high‐risk patients 15 had non‐T non‐B and 6 T ALL. Sixty of 61 patients went into complete remission. After a median observation period of 27 months, 32 of 40 low‐risk, 7 of 14 high‐risk non‐T non‐B, and none of 6 high‐risk T ALL patients were in continuous first remission. Thrity‐six of 40 low‐risk, 9 of 15 high‐risk non‐T non‐B, and none of 6 T ALL patients were alive. Despite more intensive treatment, the duration of remission and the survival were significantly shorter in the high‐risk than in the low‐risk patients. Among the high‐risk ALL, non‐T non‐B ALL did better than T ALL.
📜 SIMILAR VOLUMES
One hundred six children with newly diagnosed non-T-, non-B-cell acute lymphoblastic leukemia (ALL) were treated in a Pediatric Oncology Group (POG) pilot study in which six courses of intermediate-dose methotrexate (MTX) and cytosine arabinoside (Ara-C) (1 g/m2 each) were added to a "backbone" of s
BACKGROUND. Preventive cranial radiotherapy (CRT) in childhood acute lymphoblastic leukemia (ALL), although effective, may be associated with neurologic sequelae and second malignancies. Attempts to replace CRT with intensified intrathecal therapy (IT) have shown promise in lower risk subgroups. In